Eisai And Shionogi Develop Obesity Drug Meridia In Japan
This article was originally published in PharmAsia News
Major drug maker Eisai is aiming to launch its obesity drug Meridia (sibutramine) in two to three years. Eisai signed a licensing deal with U.S. major drug maker Abbott Laboratories and obtained exclusive rights to develop and market the drug in Japan. According to Eisai, Japanese domestic clinical trials have shown efficacy in weight loss. The company has submitted an NDA with the Ministry of Health, Labor and Welfare. Shionogi also plans to develop an obesity agent in 10 years. (Click here for more - Japanese language
You may also be interested in...
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.